Targeted radiation weapon tested against tough bone cancer
NCT ID NCT07357519
Summary
This study is testing a new drug called LNTH-2403 for people whose osteosarcoma (a type of bone cancer) has come back or hasn't responded to standard chemotherapy. The drug is designed to deliver radiation directly to cancer cells using a special targeting system. Researchers will first find the safest dose and then see if it can help control the cancer and keep it from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED / REFRACTORY OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.